Review of Late Cardiac Complications After RT With or Without Chemotherapy (Ct) Assessed by 201Tl MPI
| Reference | No. of assessable/scintigraphically examined patients (disease) | Relevant exclusion criteria and cardiovascular risk factors | Follow-up period (y) | Radiotherapy protocol | Type of isotope | Method of evaluation | Normal MPI results |
|---|---|---|---|---|---|---|---|
| Morgan et al. (63) | 25/25 (HD) | History and symptoms of cardiac disease not allowed; thyroid and pulmonary function assessed; age <35 y; Ct in 11/25 patients | 5–16 | 40 Gy, 2.2 Gy/fraction | 201Tl | Planar | 25/25 |
| Savage et al. (64) | 16/12 (HD) | History and symptoms of hypertension and coronary artery disease not allowed; age <52 y; non–anthracyclin-including Ct in 5/12 patients | 2.5–21.5 | 38.7–45.5 Gy in group 1 (n = 6, heart entirely irradiated); 30.6–44.2 Gy in group 2 (n = 10, LV partially shielded), 1.5–2 Gy/fraction | 201Tl | Planar | 12/12 |
| Constine et al. (54) | 50/38 (HD) | History and symptoms of hypertension and coronary artery disease not allowed; age <50 y at RT; Ct in 17/50 patients (in 3/17, adriamycin) | 1.1–29.1 | 18.5–47.5 Gy, 1.5–2 Gy/fraction | 201Tl and 99mTc-sestamibi | SPECT | 36/38 |
| Cowen et al. (67) | 17/17 (left-side BC) | History and risk factors of coronary artery disease not allowed; age <75 y; no previous Ct | 4.3–5.4 | Breast or chest wall: 46 Gy; internal mammary nodes: 50 Gy, mixed γ and β | 201Tl | Planar | 17/17 |
| Gustavsson et al. (71) | 26/23 (HD) | Age <45 y; no previous Ct; cardiac complications in 4/26 patients | 10–20 | 35–43 Gy, 1.5 Gy/fraction | 201Tl | SPECT | 9/23 |
| Maunoury et al. (72) | 31/25 (HD) | History of cardiac disease not allowed; age <45 y; adriamycin-containing Ct in 5 of 16 patients | 3–11 | 39–42.5 Gy, 1.8–2.5 Gy/fraction | 201Tl | SPECT | 4/25 |
| Pierga et al. (73) | 32/26 (HD) | Obesity, hypertension, smoking, diabetes, hypercholesterolemia, family history of coronary artery disease, and history and symptoms of coronary artery disease not allowed; age <45 y; adriamycin-containing Ct in 5 of 18 patients | 3–13 | 31–42.5 Gy, 1.8–2.5 Gy/fraction | 201Tl | SPECT | 4/26 |
| Girinsky et al. (65) | 42/41 (HD) | History of cardiac disease not allowed; age <41 y; Ct (MOPP and MOPP/ABVD) in 27/41 patients | 2.3–17.3 | 31–42.5 Gy, 1.8–2.5 Gy/fraction | 201Tl | SPECT | 9/41 |
HD = Hodgkin’s disease; LV = left ventricle; BC = breast cancer; MOPP = mechlorethamine, vincristine, procarbazine, and prednisone; ABVD = adriamycin, bleomycin, vinblastine, and dacarbazine.